Filkri FDA Approval History: A Comprehensive Guide

In recent years, the United States Food and Drug Administration (FDA) has expanded access to high-quality biosimilar medicines that improve patient care and affordability. One of the latest additions to this growing list is Filkri (filgrastim-laha), a new biosimilar to Neupogen. This medication was officially approved by the FDA on January 15, 2026, marking an important milestone for patients who require treatment for neutropenia and related conditions.

In this comprehensive guide, we explore the history and significance of Filkri’s approval. We also cover the science behind biosimilars, how Filkri is used in clinical practice, important safety information, and its comparison to earlier biosimilar approvals.

What Is Filkri?

Filkri is the brand name for filgrastim-laha, a biosimilar to Neupogen. It is manufactured by Accord BioPharma Inc. and approved for multiple uses related to neutropenia, a condition with low levels of neutrophils, which are white blood cells essential for fighting infections.

Filkri belongs to a class of biologic medicines called granulocyte colony-stimulating factors (G-CSFs). These medications stimulate the bone marrow to produce more neutrophils. Like Neupogen, Filkri is produced through recombinant DNA technology and administered by subcutaneous injection or intravenous infusion.

FDA Approval of Filkri: Key Dates and Regulatory Pathway

The FDA approved Filkri on January 15, 2026, as a biosimilar to Neupogen. This approval means the product has been scientifically shown to be highly similar to Neupogen, with no clinically meaningful differences in safety, purity, or potency.

Filkri was evaluated under the FDA’s biosimilar pathway, which was established by the Biologics Price Competition and Innovation Act (BPCIA). This legislation allows biosimilar manufacturers to demonstrate similarity to an existing biologic using analytical studies, animal data, and clinical evidence. Once similarity is proven, the FDA may approve the product as a biosimilar.

The 2026 approval of Filkri demonstrates the FDA’s commitment to expanding safe and effective alternatives to branded biologics, especially when patents expire and more affordable options become available.

Clinical Indications for Filkri

Filkri is indicated for the treatment of several conditions in which neutrophil production needs enhancement. These include:

• Decreasing the incidence of infection caused by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs with a high risk of severe neutropenia.
• Reducing the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy in patients with acute myeloid leukemia (AML).
• Decreasing the duration of neutropenia and its clinical consequences such as febrile neutropenia in patients undergoing myeloablative chemotherapy followed by bone marrow transplantation.
• Reducing severe neutropenia effects such as fever, infections, or ulcers in patients with congenital, cyclic, or idiopathic neutropenia.
• Increasing survival in patients exposed to myelosuppressive doses of radiation, for example in hematopoietic syndrome of acute radiation syndrome.

These indications align closely with those of Neupogen, which has been a key therapy for neutropenia and related conditions for decades.

How Filkri Works: Mechanism of Action

Filkri contains filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). G-CSF is a naturally occurring protein that regulates the production of neutrophils in the bone marrow. By binding to specific receptors on precursor cells, filgrastim stimulates the proliferation, differentiation, and activation of neutrophils.

This mechanism is essential for patients receiving chemotherapy, radiation, or bone marrow transplantation. These therapies often reduce white blood cell counts, increasing the risk of infection. Filkri helps restore neutrophil counts, reducing infection risk and improving clinical outcomes.

Filkri Compared to Other Filgrastim Biosimilars

Filkri is the fifth biosimilar to Neupogen approved by the FDA. Previous approvals include:

• Zarxio (filgrastim-sndz), approved in 2015 as the first filgrastim biosimilar in the U.S.
• Nivestym (filgrastim-aafi), approved in 2018
• Releuko (filgrastim-ayow), approved in 2022
• Nypozi (filgrastim-txid), approved in 2024

These biosimilars share similar clinical uses and mechanisms. All are approved as biosimilars without an interchangeable designation. Being designated as “biosimilar” rather than “interchangeable” means the FDA has not approved substitution at the pharmacy level without prescriber involvement.

The addition of Filkri provides clinicians and patients more options for managing neutropenia and its complications, improving accessibility and competition in the biologics market.

Administration and Dosage

Filkri is administered by subcutaneous injection or intravenous infusion, depending on the clinical setting and patient needs. Healthcare professionals determine dosing based on the indication, patient weight, and clinical response.

Prefilled syringes with standard dosing options help streamline administration and improve convenience for clinical and outpatient settings.

Safety Profile and Warnings

Filkri has been shown to be highly similar to Neupogen, with no clinically meaningful differences. However, it carries important warnings and precautions that healthcare providers and patients should consider. These include:

• Splenic rupture, where patients reporting left upper abdominal pain should be evaluated for an enlarged spleen or rupture
• Acute respiratory distress syndrome (ARDS), requiring discontinuation if patients develop acute respiratory symptoms or lung infiltrates
• Serious allergic reactions, including anaphylaxis
• Sickle cell crises, requiring monitoring and discontinuation if complications occur
• Glomerulonephritis and other renal issues
• Myelodysplastic syndrome and acute myeloid leukemia in certain patients, requiring careful monitoring
• Thrombocytopenia, requiring platelet count monitoring

Common adverse reactions vary by indication but may include fever, pain, rash, cough, difficulty breathing, nosebleeds, anemia, headache, and hair loss.

Why Biosimilars Matter

Biosimilars like Filkri play an essential role in modern healthcare. They provide cost-effective alternatives to branded biologics, maintain high standards for safety and efficacy, and increase competition in the biologics market. The FDA’s rigorous biosimilar approval process ensures that patients receive products that are highly similar to existing therapies.

Expanding the number of available biosimilars improves access to critical therapies for neutropenia and related conditions, especially for patients undergoing chemotherapy or bone marrow transplants.

Future Outlook

With the introduction of Filkri and other biosimilars, the biologic therapy landscape continues to evolve. Increased availability demonstrates the FDA’s commitment to promoting biosimilar development and improving patient access. Ongoing research and regulatory support will likely lead to more biosimilars entering the market, potentially lowering overall treatment costs while maintaining high therapeutic standards.

Conclusion

Filkri’s FDA approval in January 2026 is a significant addition to the biologics landscape. As a biosimilar to Neupogen, Filkri offers clinicians and patients another effective option for managing neutropenia across various clinical settings. Its approval reflects decades of scientific progress in biologics manufacturing and regulatory science.

Understanding Filkri’s indications, mechanisms, and safety considerations is essential for healthcare providers and patients. Informed decision-making ensures that high-quality, affordable biologic therapies are accessible to those who need them most.

Sources

• Original New Drug Application Approvals by US FDA, January 1-15, 2026, MIMS Hong Kong
• Nypozi (filgrastim-txid) biosimilar details
• Biosimilar history and list including Zarxio, Nivestym, Releuko
• Filgrastim biosimilars context, Wikipedia

Disclaimer

This blog post is for informational purposes only. It is not medical advice and should not replace consultation with a qualified healthcare professional. Always refer to official prescribing information and consult healthcare providers before making decisions about medications.